Several articles have appeared over the last years devoted to mental side effects during zonisamide (ZNS) treatment. In this study, we were particularly interested in psychotic episodes. Seventy-four epileptic patients with a history of ZNS treatment were surveyed retrospectively over the period spanning 1 March 1984 to 30 June 1994. They were divided into two groups according to the presence or absence of psychotic episodes during ZNS treatment. We analysed various factors pertaining to psychotic episodes during ZNS treatment. Of the 74 patients 14 had psychotic episodes. We found that the incidence of psychotic episodes during ZNS treatment was several times higher than the previously reported prevalence of epileptic psychosis, and that the risk of psychotic episodes was higher in young patients. In 13 patients, psychotic episodes occurred within a few years of commencement of ZNS. In children, obsessive-compulsive symptoms appeared to be related to psychotic episodes. It is important to terminate ZNS as soon as possible if psychotic episodes develop and never restart, even if seizures become worse. It cannot definitely be proved that ZNS causes psychotic episodes, as information on mental side effects during ZNS monotherapy is scant, but it does appear likely that ZNS contributes to psychotic episodes during polytherapy.
INTRODUCTION
It has been more than 10 years since zonisamide (ZNS) (1,2-benzisoxazole-3-methanesulfonamide) treatment was first used in Japan. All drugs have side effects and ZNS is no exception. A number of articles have appeared over the last few years devoted to the clinical study of psychosis during ZNS treatment [1] [2] [3] [4] . In this study, we focused on psychotic episodes during ZNS treatment and analysed various related factors.
Zonisamide is an antiepileptic drug (AED) with a basic skeleton of benzisoxazole, and a similar antiepileptic profile to those of carbamazepine (CBZ) and phenytoin (PHT) 5 . The antiepileptic action of ZNS is to suppress epileptogenic focus and subsequent seizure propagation 6 . It is also effective psychopharmacologically in treating affective disorders (i.e. manic state in bipolar disorder) 7 . Yagi and Seino 8 , however, reported a number of acute side effects with ZNS: drowsiness, ataxia, loss of appetite, decreased § E-mail: paf01635@nifty.ne.jp spontaneity, slowing of mental activity and skin lesions. Berent et al. 9 reported that ZNS affected cognitive functions, although Kubota et al. 10 reported that ZNS did not affect the event-related potential: p300. In addition, several articles have noted certain mental side effects with ZNS: depression, psychotic episode and behaviour disorder 4, 11 . However, it should be noted that these mental side effects have usually appeared during polytherapy with AEDs, rarely during monotherapy with ZNS 4 . It remains unclear, therefore, as to whether these mental side effects during polytherapy were actually due to ZNS, because of the prevalence of epileptic psychosis, as previously reported, 2.4-4.4% 12 and the fact that other AEDs also engender mental side effects 13 . Questions, then, arise as to the incidence of and factors related to ZNSinduced mental side effects. Here, we were particularly concerned with psychotic episodes, being the severest and those which most seriously affect the quality of life. The two most prominent cases are presented in detail.
MATERIALS AND METHODS
Seventy-four epileptic patients with a history of ZNS treatment were surveyed retrospectively over the period spanning 1 March 1984 to 30 June 1994. In this study, we defined psychotic episode as being in a state of delusion and/or hallucination. Therefore, patients with psychotic episodes met the ICD-10 criteria for organic delusional (schizophrenia-like) disorder and organic hallucinosis. In other words, psychotic episode here does not include organic mood (affective) disorders. Patients were divided into two groups according to the presence or absence of psychotic episodes during ZNS treatment: a psychotic group and a control group, respectively. We analysed the following factors: gender, age, age at onset of epilepsy, period of epilepsy, frequency of seizures, classification of epilepsy, period of AEDs treatment, period of ZNS treatment, histories of PHT and/or CBZ, lesions in imaging studies, neurotic symptoms, personality disorders and mental retardation. We focused on PHT and CBZ as our AEDs as they are the two most commonly used in combination with ZNS. Gender, frequency of seizures, classification of epilepsy, and history of PHT were analysed using a χ 2 -test. History of CBZ, presence of lesions in imaging studies, neurotic symptoms, personality disorders and mental retardation in the two groups were analysed using Fisher's exact probability test. Classification of epilepsy was diagnosed with history, interictal and ictal EEG according to ILEA classification. Frequency of seizures consisted of two categories: (1) frequent seizures occurring daily, weekly, or monthly, and (2) rare seizures occurring yearly or seizure free. Classification of epilepsy consisted of three categories: (1) temporal lobe epilepsy (TLE); (2) partial epilepsy (non-TLE); (3) generalized epilepsy. 'History of PHT treatment or CBZ treatment' was defined as the presence of either treatment during ZNS treatment in the control group, and as the presence of either treatment at the onset of psychotic episode in the psychotic group. One patient from the control group and one patient from the psychotic group were absent from the imaging study, and were, therefore, excluded from the analysis thereof. Neurotic symptoms consisted of anxiety symptoms, obsessive-compulsive symptoms, dissociative symptoms and somatoform symptoms; patients with neurotic symptoms met the ICD-10 criteria for organic anxiety disorder, organic dissociative disorder, organic emotionally labile disorder, and other specified mental disorders due to brain damage and dysfunction and to physical disease. Patients with personality disorders met the ICD-10 criteria for organic personality disorder. Age, age at onset of seizure, period of epilepsy and period of AEDs treatment in each group were analysed statistically using an unpaired Student's t-test. Period of ZNS treatment was analysed using the Mann-Whitney test. 'Age' was defined as age on 30 June 1994 in the control group, and as age at the onset of psychotic episode in the psychotic group. 'Period of AEDs treatment and ZNS treatment' was defined as the period from the beginning of each treatment to 30 June 1994 in the control group, and as the period from the beginning of each treatment to the onset of psychotic episodes in the psychotic group.
PROMINENT CASES Case 14
A 45-year-old male patient with frontal-lobe epilepsy (FLE); paralysis of the left upper and lower extremities had developed at the age of 44. A CT scan demonstrated a brain tumour in the right frontal lobe, which was then totally removed on 2 September 1991 in the department of neurosurgery at Hokkaido University Hospital. The tumour was histologically diagnosed as glioblastoma, and irradiation therapy and chemotherapy were carried out. The first seizure occurred just after the operation and was described as a motor seizure in the left upper extremity. Therapy with AEDs was then started (ZNS at a dosage of 200 mg day −1 and PHT at a dosage of 300 mg day −1 ). He left the hospital 1 month after the operation, and his mental state showed no change when compared with that of his presurgery state. Insomnia, loss of appetite, hypobulia, and loss of interest developed after the dosage of ZNS was increased to 300 mg day −1 following a second motor seizure on 18 December. A psychotic episode consisting of visual hallucination and delusion of reference appeared in the last week of January 1992. He was then admitted to the department of psychiatry and neurology on 30 January. ZNS was decreased promptly, later to be discontinued, and antipsychotic drugs introduced. His psychotic episodes then ceased immediately, never to reappear after the withdrawal of antipsychotic drugs.
Case 2
A girl with FLE; birth and psychomotor development were initially normal. Complex partial seizures (CPSs) began in May 1986 when she was 6 years old, 3 days after the onset of scarlet fever. These seizures consisted of a frightened expression and motor automatisms (e.g. climbing, jumping and screaming). Therapy with AEDs was commenced using sodium valproate and CBZ, 10 days after the onset of epilepsy. She visited our epilepsy clinic in October 1986. Because she later developed CPSs and secondary generalized seizures daily, ZNS was added to PHT monotherapy in May 1991 when she was 12 years old. Although ZNS proved effective, tic, a psychotic episode with auditory hallucinations and delusions of persecution and reference, and obsessional thoughts appeared 2 months after its introduction. It was immediately withdrawn and the psychotic symptoms disappeared. Therapy with ZNS was tried again several times in an attempt to control refractory seizures, although each time these psychotic symptoms would reappear, only to disappear again when treatment was withdrawn. Primidone was added in March 1992. Because her psychotic episode became irreversible in May, when she was 13 years old, she was admitted to the department of psychiatry and neurology. Although ZNS was discontinued, the psychotic episodes showed only a slight improvement. Ictal EEG during admission demonstrated spikes in the left frontal area and delta activity spreading from the left frontal area to all the other areas. CPSs consisted of staring, screaming, tonic arrest and autonomic symptoms (e.g. mydriasis, pilo-erection of skin, incontinence of urine), and had a tendency to be nocturnal and occur in clusters. These findings indicated a left medial frontal lobe origin.
RESULTS
Fourteen (18.9%) of the 74 patients exhibited psychotic episodes during ZNS treatment. Table 1 shows the clinical profiles and factors of the psychotic group. Table 2 shows the numbers for each factor in both groups. There were significantly more male patients than female patients in the psychotic group (P < 0.05). Patients with psychotic episodes were significantly younger than those without (P < 0.01). Differences in age at onset of epilepsy, classification of epilepsy and frequency of seizure between the two groups were not significant. Period of epilepsy (P < 0.01), AEDs treatment (P < 0.01) and ZNS treatment (P < 0.01) were significantly shorter in the psychotic group than in the controls. Histories of PHT and CBZ were not significant. The presence of lesions in imaging studies was not significant. The presence of neurotic symptoms was significantly higher in the psychotic group than in the control group (P < 0.05). Presence of personality disorders and mental retardation showed no significant differences.
DISCUSSION
Using ICD-10 criteria for retrospective diagnosis is rather unreliable. However, we did so in order to be clear what patients with psychotic episodes meant in this study. We consulted a number of clinical records compiled by various qualified psychiatrists, almost half of which were written by ourselves, in order to make this ICD-10 diagnosis.
In this study, we investigated only psychotic episodes. Several cases of depression during ZNS treatment have been reported 4 . It has been shown that ZNS is effective in treating affective disorders psychopharmacologically (i.e. manic state in bipolar disorder) 7 .
Case 14 was an FLE patient who had had a brain tumour removed, and in whom there was a clear correlation between psychotic episodes and ZNS treatment, with psychotic episodes occurring just after an increase of ZNS dosage and disappearing immediately after its withdrawal. The course of the psychotic episodes here suggests that they were induced by ZNS.
Case 2 was a girl with FLE. Here, each repetition of ZNS treatment caused psychotic episodes to recur. Initially, her psychotic episodes had been reversible. However, their becoming irreversible was probably caused by repeated application of ZNS treatment. Let us stress, then, that ZNS treatment must be permanently discontinued if psychotic episodes occur.
In 10 out of the 14 patients with psychotic episodes, antipsychotic medication was effective and they made a good recovery. In three (cases 1, 2 and 3) of the four remaining cases, psychotic episodes had occurred during their teens (12, 12, and 17 years old, respectively).
One multi-institutional study reported that the incidence of psychotic episodes during ZNS treatment over a period of 38 months was 1.1% 14 . However, in this study, that for a period of 124 months was found to be 18.9% (14 of 74). One reason for the higher incidence in our study is that five of the patients had consulted our clinic specifically for treatment for psychotic episodes. Even if they were excluded though, the corrected incidence would still be higher at 13.0% (9 of 69) than that in the previous study. Its incidence was also several times higher than the previously reported prevalence of epileptic psychosis (i.e. 2.4-4.4%) 12 and higher than that of epileptic psychosis in TLE (i.e. 10.3%) 15 .
In this study, there were more males than females in the psychotic group. However, gender distribution of schizophrenia-like psychosis in epilepsies appears to be almost even from previous studies 12 . Gender differences in the incidence of psychotic episodes during ZNS treatment have not been reported. We have only limited information on sex distribution and there is room here for further investigation.
Several articles have reported a correlation between age at onset of epilepsy and psychotic symptoms 16, 17 . However, age at onset of epilepsy showed no significant difference between the two groups in this study, agreeing with other reports that found no significant difference between psychotic and non-psychotic epileptic populations 12 . Period of epilepsy in the psychotic group was 13 years, shorter than that in previous studies (i.e. 15-22 years), and the onset of psychotic episode was 27.9 years old, younger than that in previous studies (i.e. 30-34 years old) 12 . These results suggest that ZNS shortened the time to the onset of psychotic episode, or possibly even caused psychotic episodes.
The psychotic group was younger than the control group. This suggests that care should be taken in introducing ZNS in younger patients, particularly children. Indeed, ZNS appears to have contributed to psychotic episodes in two children (cases 1 and 2). In addition, psychotic episodes in these cases proved refractory to antipsychotic drugs. Kimura also reported that ZNS caused behaviour disorders in two children 11 . It is obvious, therefore, that ZNS can induce mental side effects in children.
In half of the psychotic patients, psychotic episodes occurred within 1 year. Four patients developed them within a period of 1-3 years; 11 out of the 14 patients showed them within 3 years. This suggests that patients should be carefully monitored for a 3-year period following on from the commencement of treatment with ZNS.
There is no significant difference in frequency of seizure between the two groups. No paradoxical normalization was observed in the psychotic group. Case 5 showed psychosis after a cluster of CPS. The others showed no correlation between psychotic episodes and seizures.
The past few decades have seen a number of reports on the relation between psychosis and TLE, especially left focus 16, 17 , and a number of TLE patients exhibiting psychotic episodes during ZNS treatment have been reported [1] [2] [3] [4] . Some studies 1, 4 have reported that the incidence of psychosis during ZNS treatment was higher in TLEs than in non-TLE partial epilepsies. However, the incidence of psychotic episodes was not found to be higher in the TLEs in this study. Let us stress that psychotic episodes can occur in any type of epilepsy during ZNS treatment. A number of cases of generalized epilepsies have been reported 4, 18 .
Psychotic episodes during ZNS monotherapy have rarely been reported 4 . All the cases with psychotic episodes in this study were under polytherapy. Although several articles have reported a relation between psychosis and the combination of ZNS and PHT, no significant difference was shown here between PHT and CBZ in combination with ZNS.
The assumption that disturbances in the cerebral mono-amine metabolism may underlie epileptic psychosis is widely accepted 19 . From this point of view, it would not be appropriate to assert that a combination of ZNS with CBZ is safer than that with PHT, as both ZNS and CBZ increase the extracellular and intraneuronal levels of dopamin in the striatum and hippocampus in rat at a therapeutic dosage 20 , whereas PHT does not 21 .
There were more patients with neurotic symptoms in the psychotic group than in the control group. The important point to note here is that two of the children showed obsessive-compulsive symptoms just before (case 1), or almost concurrently (case 2), with the onset of psychotic episodes. This suggests that such obsessive-compulsive symptoms may be related to psychotic episode. Therefore, especially in the case of children, it is important to terminate ZNS treatment immediately should such obsessive-compulsive symptoms occur.
Slater and Beard reported that 51 out of 69 cases of schizophrenia-like psychosis in epilepsy showed signs of personality disorders. However, only two patients were recorded as schizoid and nine as paranoid. They concluded, therefore, that premorbid personality was not related to psychosis 16 . Our result, that the presence of personality disorders did not show a significant difference between the two patient groups, concurs with their view.
In the research of Jensen and Larsen 22 , psychotic epilepsy patients were of higher intelligence and achievement than non-psychotic epilepsy patients. We found no difference between our two patient groups as regards the presence of mental retardation. Mental retardation, therefore, probably does not contribute to psychotic episodes during ZNS treatment.
To summarize, this study revealed that the incidence of psychotic episodes during ZNS treatment was several times higher than the previously reported prevalence of epileptic psychosis, and that the risk of psychotic episodes was higher in young patients. In 13 out of the 14 patients, psychotic episodes occurred within a few years of starting ZNS. In children, obsessivecompulsive symptoms appear to be related to psychotic episodes during ZNS treatment. It is important to permanently withdraw ZNS as soon as possible should psychotic episodes develop, even if seizures worsen. It cannot definitely be proved that ZNS causes psychotic episodes as information on mental side effects during ZNS monotherapy is scant. However, it seems likely that ZNS contributes to psychotic episode during polytherapy.
